KYMOS offers bioanalytical testing services by means of the Mesoscale Discovery Platform for quantification of biological drugs, antibodies and biomarkers.
KYMOS offers bioanalytical testing services by means of the Mesoscale Discovery Platform for quantification of biological drugs, antibodies and biomarkers.
This multi-array technology is faster, easier, more sensitive and covers a broader dynamic range than ELISA, quantifying up to 10 analytes in single well, whether you are multiplexing biomarker and cytokine assays, testing for immunogenicity or toxicity, or developing your own unique assays.
The advantages of electrochemiluminescence (ECL) in front of other most common techniques are: high sensitivity, broad dynamic range, low background, easy to use, use of stable, non-radioactive and well conjugated labels.
MULTI-ARRAY technology combines electrochemiluminescence and arrays to bring speed and high density of information to biological assays. In combination with MULTI-SPOT plates, this technology enables precise quantitation of multiple analytes in a single sample exacting less time and effort.